推荐产品
等級
pharmaceutical primary standard
API 家族
oxaliplatin
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N
InChI
1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
InChI 密鑰
ZROHGHOFXNOHSO-BNTLRKBRSA-L
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Oxaliplatin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Oxaliplatin Injection
- Oxaliplatin for Injection
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Danger
危險分類
Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
L B J van Iersel et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(11), 1557-1563 (2014-08-16)
To improve isolated hepatic perfusion (IHP), we performed a phase I dose-escalation study to determine the optimal oxaliplatin dose in combination with a fixed melphalan dose. Between June 2007 and July 2008, 11 patients, comprising of 8 colorectal cancer and
Maire F Osborn et al.
ACS chemical biology, 9(10), 2404-2411 (2014-07-24)
With the importance of RNA-based regulatory pathways, the potential for targeting noncoding and coding RNAs by small molecule therapeutics is of great interest. Platinum(II) complexes including cisplatin (cis-diamminedichloroplatinum(II)) are widely prescribed anticancer compounds that form stable adducts on nucleic acids.
Jennifer R Deuis et al.
Neuro-oncology, 16(10), 1324-1332 (2014-04-10)
Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on
Hirofumi Yasui et al.
Journal of cancer research and clinical oncology, 141(1), 153-160 (2014-08-12)
The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at
Hailiang Wu et al.
Journal of controlled release : official journal of the Controlled Release Society, 189, 1-10 (2014-06-24)
Nanocarriers have been used for specific delivery of therapeutic agents to solid tumors based on the enhanced permeability and retention in cancerous tissues. Despite metastasis is the main reason of cancer-related death and a priority for nanocarrier-based therapies, the targeting
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门